PHVS: Pharvaris NV Kompaniya qiymatining sof foydaga nisbati
Pharvaris N.V. (PHVS) qimmatli loyihalar portfeli bilan irsiy angioedema uchun oral terapiya vositalarini ishlab chiqadi. Kompaniyaga tegishli P/E koeffitsiyenti aktivning investitsiya jozibadorligini ob'ektiv ravishda aks ettiradi va hozirda ushbu ko'rsatkich -11.70 darajasida turibdi. Tabletka shakllariga o'tish logistikani soddalashtiradi va mijozlar bazasini kengaytiradi. Biroq, yuqori R&D xarajatlari va daromad yetishmasligi rezervlarning kamayishiga hamda tashqi kapital qidiruviga olib kelmoqda.
%20P%2FE%20multiplikatori&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_PHVS_-_Pharvaris-N.V._-_PE-Multiple "PHVS: Pharvaris N.V. Biznesning o‘zini qoplash muddati 04.07.2022 - 14.11.2026 | 👁️GURU.Markets👁️")
Pharvaris Pharma (PHVS) kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati Pharvaris N.V.|PHVS - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati pharvaris.com|PHVS - Kompaniya qarzlari|Qarzning balans qiymatiga nisbati Pharvaris NV|PHVS - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz Pharvaris|Kritik likvidlik koeffitsiyenti pharvaris.com
- foyda va bozor multiplikatorlari tafsilotlari:
PHVS - Sof foyda|Kutilayotgan sof daromad Pharvaris N.V.|PHVS - P/E multiplikatori|Forvard P/E multiplikatori Pharvaris Pharma|PHVS - Narxning foydaga va o‘sish sur’atiga nisbati|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Pharvaris Pharma|PHVS - Eskirish chegirilmasdan oldingi operatsion foyda|So'nggi o'n ikki oy davomida bir aksiya uchun foyda Pharvaris|PHVS - Bir aksiya uchun sof foyda (EPS TTM)|Choraklik EPS foyda o'sishi pharvaris.com|PHVS - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning kutilayotgan dinamikasi Pharvaris N.V.
- realizatsiya hajmi va tushum ko'rsatkichlari:
Kompaniyaning har tomonlama tahlili:Pharvaris PHVS
Klinik yo'l xaritalarining shaffofligi va Pharvaris N.V. rahbariyatining yuqori ilmiy ekspertizasi investorlarga GURU.Markets platformasidagi kompaniyaning joriy P/E ko'rsatkichi orqali har bir foyda birligining qiymatini baholash imkonini beradi. -11.70 qiymati biznes kapitalizatsiyasiga bo'lgan bozor kutganlarini aks ettiradi, bunda past ko'paytirgichlar yo qadrsizlanganlikni, yoki biotexnologiya sektori doirasidagi tizimli risklarni signalizatsiya qilishi mumkin.
Muhim raqobatchilar
P/E multiplikatori Argenx|Narx-foyda koeffitsiyenti BNTX (BioNTech Group)|ABVX (abivax.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ADMA (admabiologics.com)|Biznesning o‘zini qoplash muddati protagonist-inc.com (PTGX)|IMVT - Narxning foydaga nisbati|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Narx-foyda koeffitsiyenti|Grifols Biemat (GRFS) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Adaptive Biotechnologies|Narx-foyda koeffitsiyenti CLDX|P/E multiplikatori auriniapharma.com|Narxning foydaga nisbati BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Narx-foyda multiplikatori|P/E multiplikatori DNTH (dianthustx.com)|AbCellera Bio (ABCL) - Kapitalizatsiyaning foydaga nisbati|TRML: Narx-foyda koeffitsiyenti|Kapitalizatsiyaning sof foydaga nisbati PGEN|PHAR: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Nektar Therapeutics Inc (NKTR)|Narx-foyda koeffitsiyenti UPB|Narx-foyda multiplikatori ZBIO (Zenas Biopharma, Inc.)|Narx-foyda koeffitsiyenti IMNM (Immunome Bio)|Biznesning o‘zini qoplash muddati Gossamer Bio, Inc.|P/E multiplikatori KALV (KalVista Pharma)|Septerna, Inc. (SEPN) - Kapitalizatsiyaning foydaga nisbati|PVLA - Narxning foydaga nisbati|SVRA - P/E multiplikatori|Rigel Pharmaceuticals Inc (RIGL) - Narxning foydaga nisbati|ANAB - Biznesning o‘zini qoplash muddati|Narx-foyda koeffitsiyenti ATXS|ENGN: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati RAPT Therapeutics (RAPT)|JBIO (Aerovate) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ACRS (Aclaris Therapeutics)|Kompaniya qiymatining sof foydaga nisbati KYTX|Tiziana Life Sciences - P/E multiplikatori|CABA: Narxning foydaga nisbati|VTYX: P/E multiplikatori|THTX (Theratechnologies, Inc) - Narxning foydaga nisbati|AVTX (Avalo Therapeutics, Inc.) - P/E multiplikatori|P/E multiplikatori Eledon Pharmaceuticals|Narxning foydaga nisbati Agenus Inc. (AGEN)|Narx-foyda koeffitsiyenti Climb Bio Inc. CLYM|P/E multiplikatori ZURA (Zura Bio Ltd)|ATYR - Narx-foyda koeffitsiyenti|ADAG - Narxning foydaga nisbati|IMA - P/E multiplikatori|STTK: P/E multiplikatori|Equillium Bio (EQ) - P/E multiplikatori|CNTB (connectbiopharm.com) - P/E multiplikatori|IMUX: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ATRA|P/E multiplikatori InflaRx NV (IFRX)|X4 Pharmaceuticals, Inc. (XFOR) - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori adicetbio.com ACET|Celularity - P/E multiplikatori|Kompaniya qiymatining sof foydaga nisbati INMB (INmune Bio Corp)|BRNS (Barinthus Bio) - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning sof foydaga nisbati KZR (Kezar Life Sciences)|Narxning foydaga nisbati SAB Biotherapeutics Inc.|Akari Therapeutics Plc - Kapitalizatsiyaning sof foydaga nisbati|Narx-foyda koeffitsiyenti ENLV (Enlivex Therapeutics Ltd.)|Narx-foyda koeffitsiyenti Q32 Bio Inc QTTB|Narxning foydaga nisbati geovax.com GOVX|P/E multiplikatori edesabiotech.com EDSA|iBio Corporation - P/E multiplikatori|Kompaniya qiymatining sof foydaga nisbati CARM (carismatx.com)|XTL Biopharmaceuticals Ltd. (XTLB) - Narxning foydaga nisbati|Bolt Bio (BOLT) - P/E multiplikatori|HCWB (HCW Biologics Inc) - P/E multiplikatori|Narx-foyda koeffitsiyenti Aptevo Therapeutics (APVO)|P/E multiplikatori AIM|Bozor narxining sof foydaga nisbati ADTX|P/E multiplikatori GRI (GRI Bio Corporation)|P/E multiplikatori XORTX Corp XRTX|HIND - Narxning foydaga nisbati|Revelation Biosciences (REVB) - Narx-foyda koeffitsiyenti|INDP (Indaptus Therapeutics, Inc.) - Narx-foyda koeffitsiyenti|Scinai Immunotherapeutics Ltd (SCNI) - P/E multiplikatori|CALI (CalciMedica Inc) - P/E multiplikatori|affimed.com - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati allakos.com (ALLK)|P/E multiplikatori HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Narx-foyda koeffitsiyenti|iTeos Therapeutics, Inc. (ITOS) - Kapitalizatsiyaning foydaga nisbati|OCEA: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E multiplikatori
